Akero says positive PhIIb data buck the gloomy NASH tide, but questions remain on safety front

In NASH, positive readouts don’t come too often. Yet according to Akero, today is that day. Akero reported results from its 24-week HARMONY Phase IIb trial bright and early Tuesday, looking at lead candidate and ex-Amgen drug efruxifermin, or EFX, in 128 patients with biopsy-confirmed, pre-cirrhotic NASH. And the study…

...

Click to view original post